These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36697233)

  • 1. Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.
    Kim YJ; Krainer AR
    Mol Cells; 2023 Jan; 46(1):10-20. PubMed ID: 36697233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
    Oren YS; Avizur-Barchad O; Ozeri-Galai E; Elgrabli R; Schirelman MR; Blinder T; Stampfer CD; Ordan M; Laselva O; Cohen-Cymberknoh M; Kerem E; Bear CE; Kerem B
    J Cyst Fibros; 2022 Jul; 21(4):630-636. PubMed ID: 34972649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis.
    Michaels WE; Pena-Rasgado C; Kotaria R; Bridges RJ; Hastings ML
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017302
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.
    Oren YS; Irony-Tur Sinai M; Golec A; Barchad-Avitzur O; Mutyam V; Li Y; Hong J; Ozeri-Galai E; Hatton A; Leibson C; Carmel L; Reiter J; Sorscher EJ; Wilton SD; Kerem E; Rowe SM; Sermet-Gaudelus I; Kerem B
    J Cyst Fibros; 2021 Sep; 20(5):865-875. PubMed ID: 34226157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic Acid Therapies for Cystic Fibrosis.
    Sasaki S; Guo S
    Nucleic Acid Ther; 2018 Feb; 28(1):1-9. PubMed ID: 29160746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
    Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
    Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells.
    Michaels WE; Bridges RJ; Hastings ML
    Nucleic Acids Res; 2020 Jul; 48(13):7454-7467. PubMed ID: 32520327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
    Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
    Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis.
    Zheng Z; Song Y; Tan X
    Heart Rhythm; 2023 Aug; 20(8):1169-1177. PubMed ID: 37121422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs).
    Susorov D; Echeverria D; Khvorova A; Korostelev AA
    Nucleic Acids Res; 2024 Aug; 52(15):8687-8701. PubMed ID: 39011883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.
    Sermet-Gaudelus I; Clancy JP; Nichols DP; Nick JA; De Boeck K; Solomon GM; Mall MA; Bolognese J; Bouisset F; den Hollander W; Paquette-Lamontagne N; Tomkinson N; Henig N; Elborn JS; Rowe SM
    J Cyst Fibros; 2019 Jul; 18(4):536-542. PubMed ID: 30467074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides.
    Friedman KJ; Kole J; Cohn JA; Knowles MR; Silverman LM; Kole R
    J Biol Chem; 1999 Dec; 274(51):36193-9. PubMed ID: 10593905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide-based therapies for cystic fibrosis.
    Kreda SM
    Curr Opin Pharmacol; 2022 Oct; 66():102271. PubMed ID: 35988291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steric Inhibition of 5' UTR Regulatory Elements Results in Upregulation of Human CFTR.
    Sasaki S; Sun R; Bui HH; Crosby JR; Monia BP; Guo S
    Mol Ther; 2019 Oct; 27(10):1749-1757. PubMed ID: 31351782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis.
    Beumer W; Swildens J; Leal T; Noel S; Anthonijsz H; van der Horst G; Kuiperij-Boersma H; Potman M; van Putten C; Biasutto P; Platenburg G; de Jonge H; Henig N; Ritsema T
    PLoS One; 2019; 14(6):e0219182. PubMed ID: 31251792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.